Bruker Corporation Common Stock (BRKR)
Stock · NASDAQ · Industrials
$54.8as of 10/16/2026
Price chart
Active signals
BRKR Signal Track Record
How signals performed across all stocks →What BRKR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -0.2% | 46% | September 16, 2026 |
| Bollinger Band Breakout | 26 | -1.1% | 46% | September 17, 2026 |
| Bollinger Band Breakdown | 21 | -2.6% | 48% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -3.3% | 50% | April 14, 2026 |
| Any 20-session window (baseline) | -0.1% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BRKR
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle s…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 11,085
- Website
- www.bruker.com/
Fundamentals
- 1-day range
- $54.27$57.18
- Market cap
- $7.95B
- P/E (trailing)
- —
- P/E (forward)
- 22.90
- EPS (trailing)
- $-0.47
- Dividend yield
- 0.30%
- Beta
- 1.24
- Avg. volume
- 2.27M
- Ex-dividend date
- September 21, 2026
- Dividend pay date
- October 7, 2026
How Bruker Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Bruker Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- BRKRBruker Corporation Common Stock$54.8▼ 3.08%Market cap $7.95BP/E —$32.37$66.98
- AVTRAvantor Inc. Common Stock$16.42▲ 2.05%Market cap $8.91BP/E —$7.27$16.38
- BIOBio-Rad Laboratories Inc. Class A Common Stock$353.7▼ 3.05%Market cap $9.16BP/E 43.88$236.73$396.23
- TXG10x Genomics Inc. Class A Common Stock$69.86▼ 3.49%Market cap $5.79BP/E —$11.62$102.81
- RVTYRevvity Inc. Common Stock$152.64▼ 1.34%Market cap $12.74BP/E 72.12$81.22$166.25
- EYPTEyePoint Inc. Common Stock$2.99▼ 4.78%Market cap $1.08BP/E —$2.93$19.11
- CTKBCytek Biosciences Inc. Common Stock$5.25▼ 2.96%Market cap $537.23MP/E —$3.31$6.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BRKR Bruker Corporation Common Stock | $7.95B | — | $54.8 | ▼ 3.08% | $32.37$66.98 |
| AVTR Avantor Inc. Common Stock | $8.91B | — | $16.42 | ▲ 2.05% | $7.27$16.38 |
| BIO Bio-Rad Laboratories Inc. Class A Common Stock | $9.16B | 43.88 | $353.7 | ▼ 3.05% | $236.73$396.23 |
| TXG 10x Genomics Inc. Class A Common Stock | $5.79B | — | $69.86 | ▼ 3.49% | $11.62$102.81 |
| RVTY Revvity Inc. Common Stock | $12.74B | 72.12 | $152.64 | ▼ 1.34% | $81.22$166.25 |
| EYPT EyePoint Inc. Common Stock | $1.08B | — | $2.99 | ▼ 4.78% | $2.93$19.11 |
| CTKB Cytek Biosciences Inc. Common Stock | $537.23M | — | $5.25 | ▼ 2.96% | $3.31$6.21 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesdaybenzinga · 10/14/2026
- Why Is Bruker (BRKR) Getting Attention For Its Human Plasma Proteome Atlas?Yahoo · 10/9/2026
- Bruker (BRKR), Why Is Its Latest Update Drawing Fresh Attention?Yahoo · 10/8/2026
- Bruker Gains 66.3% in a Year: What's Driving the Rally?Yahoo · 10/8/2026
- Barclays Maintains Overweight on Bruker, Raises Price Target to $70Benzinga · 10/7/2026
- 3 Cash-Producing Stocks We Steer Clear OfYahoo · 10/7/2026
- Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform ResolutionYahoo · 10/6/2026
- Are Options Traders Betting on a Big Move in Bruker Stock?Yahoo · 10/5/2026
- 1 Surging Stock to Target This Week and 2 We QuestionYahoo · 10/5/2026
Insider Activity
Insider Actions →- Mark Munch · September 15, 2026 · Option Exercise2.0K @ $22.19
- Mark Munch · September 15, 2026 · Sale2.0K @ $52.87
- Pusch Wolfgang · August 17, 2026 · Sale3.5K @ $56.9
- Pusch Wolfgang · August 15, 2026 · Grant2.5K
- Pusch Wolfgang · August 15, 2026 · Grant3.1K
- Thomas Bures · August 15, 2026 · Grant4.0K
- Srega Juergen · August 15, 2026 · Grant13.7K
- Srega Juergen · August 15, 2026 · Grant16.9K
- Burkhard Prause · August 15, 2026 · Grant2.7K
- Burkhard Prause · August 15, 2026 · Grant3.3K
- Mark Munch · August 15, 2026 · Grant11.7K
- Mark Munch · August 15, 2026 · Tax Withholding3.0K @ $57.7
- Mark Munch · August 15, 2026 · Grant14.4K
- Gerald N. Herman · August 15, 2026 · Grant12.8K
- Gerald N. Herman · August 15, 2026 · Tax Withholding2.7K @ $57.7
Institutional Ownership
March 31, 2026
- Total shares held
- 131.11M
- Total value held
- $4.58B
- Institutional holders
- 336
- Unknown17.94M
- Unknown16.10M
- Unknown11.18M
- Unknown9.48M
- Unknown4.82M
- Unknown3.91M
- Unknown3.36M
- Unknown3.27M
- Unknown2.92M
- Unknown2.58M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Bruker Unveils Proteomics Tools, Analysts Lift Targets Amid Competition
Bruker announced new timsUltra AIP and timsOmni workflows that enhance functional proteomics for drug discovery and disease biology. Analysts at Guggenheim and Leerink Partners raised their price targets to $72 and $80, respectively, reflecting confidence in the company’s growth. QIAGEN’s recent FDA‑cleared panel expansion adds competitive pressure in the diagnostics market, where Bruker also operates.
Bruker Unveils Proteomics Tools, Analysts Lift Targets Amid Competition. Bruker announced new timsUltra AIP and timsOmni workflows that enhance functional proteomics for drug discovery and disease biology. Analysts at Guggenheim and Leerink Partners raised their price targets to $72 and $80, respectively, reflecting confidence in the company’s growth. QIAGEN’s recent FDA‑cleared panel expansion adds competitive pressure in the diagnostics market, where Bruker also operates.